Skip to main content

NGM Biopharmaceuticals Inc

NGMDelisted Apr 5, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001426332

NGM Biopharmaceuticals Inc was delisted on Apr 5, 2024; its insiders filed their last Form 4 on Apr 8, 2024; 75 institutions reported holding it in 13F filings for Q1 2024, worth $55.1M in total; no superinvestor held it.

Q1 2022 vs. Q4 2021

How the institutions holding NGM Biopharmaceuticals Inc changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of NGM: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders119114−5
Shares47.1M48.1M+990.6K (+2.1%)
Value$833.5M$732.8M−$100.7M (−12.1%)

New holders (15)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to NGM in Q1 2022
InstitutionSharesValue% of portfolio
EcoR1 Capital, LLC541,108$8.25M0.26%
Woodline Partners LP471,039$7.18M0.12%
Candriam Luxembourg S.C.A.217,187$3.31M0.02%
Silverarc Capital Management, LLC200,494$3.06M1.66%
Norges Bank95,400$1.45M0.00%
Raymond James & Associates62,888$959.0K0.00%
Allianz Asset Management GmbH48,070$733.0K0.00%
HighVista Strategies LLC46,243$705.0K0.45%
Raymond James Financial Services Advisors, Inc.29,091$444.0K0.00%
Amalgamated Bank3,933$60.0K0.00%
Amalgamated Financial Corp.3,933$60.0K0.00%
Steward Partners Investment Advisory, LLC2,017$31.0K0.00%
Rockefeller Capital Management L.P.1,000$15.0K0.00%
Signaturefd, LLC72$1.00K0.00%
Allworth Financial LP13$00.00%

Sold out (20)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q4 2021 and filed for Q1 2022 without it.